14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 3.629 1 day ( 0 % )
Last Price $4.28 7.00 %
High/ Low $3.86 - $4.42 20.73%
Chg 7 Days 5.16 % $4.07 $4.28
Chg 30 Days -12.83 % $4.91 $4.28
Chg 12 mos -32.06 % $6.30 $4.28
Trend - 3 mos -7.17 % Width: 65.71 %
Trend - 12 mos -8.49 % Width: 296.08 %
Pred. range - 3 mos $3.06 - $5.08 -28.40 % - 18.65 %
Pred. range - 12 mos $1.29 - $5.11 -69.86 % - 19.36 %
Short MA avg 3 mos Buy May 08, 2024 - 7 days
Long MA avg 3 mos Buy May 15, 2024 - 2 days
Short/Long MA avg 3 mos Sell Apr 19, 2024 - 20 days
Short MA avg 12 mos Buy May 14, 2024 - 3 days
Long MA avg 12 mos Buy May 15, 2024 - 2 days
Short/Long MA avg 12 mos Sell May 10, 2024 - 5 days
Pivot Short Sell Apr 18, 2024 - 21 days
Bollinger Buy May 16, 2024 - 1 day
MACD Buy No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Prelude Therapeutics Incorporated

Prelude Therapeuticsorporated Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selecti... PRLD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT